Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Research And Development Expense of $921.93 million for the year ending 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +23.4% in Research And Development Expense from 2024 to 2025.
- This data is from BIOMARIN PHARMACEUTICAL INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), BIOMARIN PHARMACEUTICAL INC's Research And Development Expense has grown by 888.2%.
- Historical annual values: Fiscal year 2025: $921.93 million | Fiscal year 2024: $747.18 million | Fiscal year 2023: $746.77 million | Fiscal year 2022: $649.61 million | Fiscal year 2021: $628.79 million | Fiscal year 2020: $628.12 million | Fiscal year 2019: $715.01 million | Fiscal year 2018: $696.33 million | Fiscal year 2017: $610.75 million | Fiscal year 2016: $661.91 million | Fiscal year 2015: $634.81 million | Fiscal year 2014: $461.54 million | Fiscal year 2013: $354.78 million | Fiscal year 2012: $302.22 million | Fiscal year 2011: $214.37 million | Fiscal year 2010: $147.31 million | Fiscal year 2009: $115.12 million | Fiscal year 2008: $93.29 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: